Pancreatic cancer is one of the deadliest cancers globally, mainly because of its subtle onset and challenges of early detection. Patients often present with vague and non-specific symptoms like mild abdominal discomfort, which leads to diagnostic delays until the disease becomes advanced and inoperable. Only about 15 to 20% of patients are eligible for curative surgery. Many receive no treatment because of their advanced disease, frailty, or age. These diagnostic challenges not only reduce survival rates but also increase the risk of clinical management errors. Despite the importance of accurate diagnosis, limited research has examined malpractice claims across the full continuum of pancreatic cancer care. Understanding these claims may help identify systemic vulnerabilities and areas for improvement in the healthcare system.
This nationwide study in Norway aimed to explore the frequency, characteristics, and outcomes of malpractice claims related to pancreatic cancer over a decade. It focused on detecting diagnostic and management error patterns, assessing the claims approval rates, and investigating the contribution of different healthcare levels to these claims in a universal healthcare framework that uses a no-blame compensation structure.
This study used anonymized administrative data from the Norwegian System of Patient Injury Compensation (NPE), which covers all claims filed from January 2015 to December 2024 for pancreatic cancer (International Classification of Diseases, 10th Revision (ICD-10) code C25.x). Ethical approval was not required, as the data were de-identified and aggregated. The analysis included claims from the entire healthcare system, including primary care, municipal services, private diagnostic providers, and specialist hospital care. Statistical analyses were conducted using SPSS version 29. Categorical variables were analyzed using chi-square or Fisher’s exact tests, with statistical significance set at p < 0.05. The study period was divided into two intervals (2015–2020 and 2021–2024) to evaluate temporal trends.
A total of 148 malpractice claims were filed among 9,548 newly diagnosed pancreatic cancer cases during the 10-year study period. This resulted in an overall claim rate of 1.55%, or about 1 claim for every 65 cases. The median number of claims per year was 15 (range 8 to 20), and no significant differences were observed in the claim distribution in time periods, regions, or age groups. A statistically significant increase in the proportion of male claimants was noted in the later period (64% vs 48%, p = 0.049). Thirty-three (22%) of the claims were approved for compensation. The overwhelming majority (85%) were related to delayed diagnosis, which highlights this as the most critical issue in pancreatic cancer care in these approved claims.
Radiological imaging played a central role in many diagnostic delays, contributing to 18 of the 33 approved claims. Identified errors included misinterpretation of imaging, failure to act on abnormal findings, communication breakdowns among providers, and inappropriate selection of diagnostic procedures. The median diagnostic delay was approximately 6 months, with a wide range from 2–3 months to as long as 11 years, particularly in cases involving poorly monitored premalignant conditions. Clinical judgement errors, mainly involving general practitioners not pursuing necessary diagnostic tests, accounted for five claims. Other claims involved surgical complications and medication errors, although these were less common.
Sixteen out of 33 approved claims ended in patient death. Some patients experienced no measurable prognostic loss, which suggests that not all delays impacted disease outcomes. Financial compensation totalled about 16.8 million NOK (around 1.47 million EUR), averaging 525,000 NOK per claim, with a median of 187,000 NOK. The approval rates of cases varied across care levels; private diagnostic providers, specifically radiology services, had higher approval rates because of heightened expectations for diagnostic accuracy. Claims against general practitioners were less likely to be approved because of the ambiguous early disease symptoms.
Overall, malpractice claims related to pancreatic cancer were relatively infrequent but mainly arise from diagnostic delays, specifically those involving imaging and communication failures. These findings indicate missed or delayed diagnosis as an important vulnerability in pancreatic cancer care. Although underreporting of claims may occur due to patient frailty, the no-blame compensation system may enhance transparency. Efforts to improve outcomes should focus on earlier detection, improved radiological accuracy, stronger communication among care teams, and the integration of technologies such as artificial intelligence to reduce diagnostic errors.
Reference: Søreide AH, Edland KH, Alvestad AB, Hodne S, Søreide K. Malpractice claims for pancreatic cancer in Norway: claim-rates, injury domains, claim outcomes and indemnity compensation. Acta Oncol. 2026;65:273-281. doi:10.2340/ao.v65.45500
